<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738344</url>
  </required_header>
  <id_info>
    <org_study_id>YIG0122001</org_study_id>
    <nct_id>NCT04738344</nct_id>
  </id_info>
  <brief_title>Very Long Versus Overlapping Stents in Long Coronary Lesions</brief_title>
  <official_title>The Use of Very Long Versus Overlapping Drug Eluting Stents for the Management of Long Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Young Investigator Group of Cardiovascular Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Young Investigator Group of Cardiovascular Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is performed to compare the angiographic and clinical outcomes of the use of&#xD;
      single long stent versus overlapping stents in the treatment of long coronary lesions in&#xD;
      patients with chronic coronary syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) in diffuse coronary artery disease is still&#xD;
      considered a big obstacle for interventional cardiologists. Very long coronary lesions are&#xD;
      usually found, and implantation of a single stent was a great problem forcing the operator to&#xD;
      do overlapping of several stents.&#xD;
&#xD;
      Recently, new stent designs with increasing length are developed and emerging as a great tool&#xD;
      for the percutaneous treatment of long lesions. Nowadays, stents up to 60 mm are available to&#xD;
      be used in these cases reducing stent overlap.&#xD;
&#xD;
      Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention has been shown in&#xD;
      clinical trials, registries, and meta-analyses to be associated with a reduction in clinical&#xD;
      events after percutaneous coronary intervention; however, IVUS utilization during&#xD;
      percutaneous coronary intervention remains low in the United States and worldwide. The impact&#xD;
      of IVUS in these complex lesions may be associated with a lower rate of clinical adverse&#xD;
      events in comparison with angiography alone.&#xD;
&#xD;
      The study will be conducted on forty patients with chronic stable angina on maximal medical&#xD;
      treatment who are going to have elective coronary angiography and elective PCI and having one&#xD;
      long coronary lesion that is more than 40 mm in length, they will be randomized into either&#xD;
      treatment of the lesion with a single very long stent (more than 40 mm in length) or with&#xD;
      more than one overlapping stents in 1:1 randomization. Control angiography and IVUS will be&#xD;
      done to the 2 groups after 6 months and the major cardiovascular outcomes will be addressed&#xD;
      at 1,3 and 6 months follow-up periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary angiographic criteria after 6 months of stent deployment</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with any form in-stent restenosis using control coronary angiography at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(IVUS) after 6 months of stent deployment</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with any form in-stent restenosis using Intravascular Ultrasonography (IVUS) at 6 months to assess subclinical neointimal proliferation and in-stent restenosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Cardiovascular and Cerebrovascular Events (MACCE) after 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with any Major Cardiovascular and Cerebrovascular Events (MACCE) at 6 months of stent deployment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any Major Bleeding Event</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with Any Major Bleeding Event as defined by the International Society of Thrombosis and Haemostasis (fatal bleeding, and/or symptomatic bleeding in a critical organ or area, and/or bleeding causing a fall in hemoglobin level of â‰¥ 2 g/dl or 1.24 mmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Chronic Coronary Syndrome</condition>
  <condition>Drug Eluting Stents</condition>
  <arm_group>
    <arm_group_label>Percutaneous coronary intervention and stent implantation using one long stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long coronary lesions will be treated percutaneously with a single long stent (more than 40 mm in length) and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Percutaneous coronary intervention and stent implantation using more than one overlapping stents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long coronary lesions will be treated with more than one overlapping stents and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention and Stent Implantation</intervention_name>
    <description>Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.</description>
    <arm_group_label>Percutaneous coronary intervention and stent implantation using more than one overlapping stents</arm_group_label>
    <arm_group_label>Percutaneous coronary intervention and stent implantation using one long stent</arm_group_label>
    <other_name>PCI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 18 years of age&#xD;
&#xD;
          -  Single vessel disease and undergoing PCI for significant long lesion.&#xD;
&#xD;
          -  Chronic stable angina on maximal medical treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with acute coronary syndromes.&#xD;
&#xD;
          -  Patients having two or more vessel disease on coronary angiography.&#xD;
&#xD;
          -  Previous myocardial infarction.&#xD;
&#xD;
          -  Previous vascularization either by PCI or bypass grafting.&#xD;
&#xD;
          -  Very low ejection fraction less than 35%.&#xD;
&#xD;
          -  Renally impaired patients with Creatinine clearance less than 50 ml/min.&#xD;
&#xD;
          -  Contraindication to dual antiplatelet drug therapy.&#xD;
&#xD;
          -  Contraindication to coronary angiography.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed A Sobhy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alexandria - Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amr Zaky, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alexandria - Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed M El Amrawy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alexandria - Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed M El Amrawy, MD</last_name>
    <phone>+201006222922</phone>
    <email>dr.ahmed.elamrawy@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Naguib, MSc</last_name>
    <phone>+201003756413</phone>
    <email>drahmednaguib@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alexandria</name>
      <address>
        <city>Alexandria</city>
        <zip>21321</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Naguib, MSc</last_name>
      <phone>+201003756413</phone>
      <email>drahmednaguib@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ahmed M El Amrawy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Naguib, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdallah Almaghraby, Msc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Cardiac Center (ICC)</name>
      <address>
        <city>Alexandria</city>
        <zip>21524</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed El Amrawy, MD</last_name>
      <phone>+201006222922</phone>
      <email>dr.ahmed.elamrawy@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ahmed M El Amrawy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Naguib, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVUS</keyword>
  <keyword>Drug Eluting Stents</keyword>
  <keyword>Chronic Coronary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD may be shared with researchers if requested</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

